ArticleCancer immunology, immunotherapy : CII2025
Nonclinical safety evaluation and pharmacokinetics of Ab612, a novel anti-L1CAM (CD171) therapeutic antibody candidate against solid cancer.
Se-Ho Kim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.